



## Rohini K. Chintalapally, MD

---

Rohini K. Chintalapally, MD treats all forms of cancer and blood disorders at Northwest Georgia Oncology Centers, P.C. She has a special interest in treating breast and lung cancers. Dr. Chintalapally received her medical degree at Kasturba Medical College in India and conducted her internship, residency and fellowship at Medical College of Georgia in Augusta. She is currently active in cancer research and clinical trials to provide her patients with the most advanced cancer treatment available in Georgia. Dr. Chintalapally provides patient-centered cancer care at NGOC's Douglasville Center.

Medical Education	M.D., 03/2008 Kasturba Medical College Manipal, Karnataka, India
Postdoctoral	<p>Internship (Internal Medicine) Medical College of Georgia (MCG), Augusta University Augusta, Georgia 07/2012 to 07/2013</p> <p>Residency (Internal Medicine) Medical College of Georgia (MCG), Augusta University Augusta, Georgia 07/2013 to 08/2015</p> <p>Fellowship (Hematology/Oncology) Medical College of Georgia (MCG), Augusta University Augusta, Georgia 08/2015 to 07/2018</p>
Investigator Training	<p>NCI Investigator Number: Pending Protection of Human Subjects: Certification Entity, Completion Date, Pending Good Clinical Practice: Certification Entity, Completion Date, Pending</p>
Board Certification	<p>State of Georgia, Physician License #74561 National Provider Number (NPI): 1861756694 American Board of Internal Medicine, Internal Medicine, 2015 American Board of Internal Medicine, Medical Oncology, 2018 American Board of Internal Medicine, Hematology, 2018</p>
Experience	<p>Physician, Medical Oncology &amp; Hematology Northwest Georgia Oncology Centers, PC, Cartersville, Georgia July 2021 to Present</p> <p>Physician, Medical Oncology &amp; Hematology Lewis Hall Singletary Oncology Center, Archbold Medical Center, Thomasville, Georgia August 2018 to June 2021</p> <p>Clinical Assistant Professor, Medical Oncology &amp; Hematology Florida State University, College of Medicine, Tallahassee, Florida June 2019 to June 2021</p> <p>Medical Doctor Vivek Hospital Hyderabad, India April 2008 to March 2011</p>

Professional Societies	Member, American Society of Clinical Oncology Member American Society of Hematology Member American College of Physicians Member Georgia Society of Clinical Oncology
Publications	<p>1. Prognostic value of complete remission with superior platelet counts in Acute Myeloid Leukemia. J Community Support Oncol 2016 Feb;14(2):66-71 Mangaonkar, A., Hongyan, Xu., Chintalapally, R., Jillela, A., Kota, Vamsi.</p> <p>2. Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia Case Rep Hematol 2015 8;2015:576042. Epub 2015 Oct 8. Mangaonkar, A.,Mansour, J., Chintalapally, R, Kota, Vamsi.</p> <p>3. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic Review of immune-related adverse events in cancer trials Crit Rev Oncol Hematol. 2017 Nov;119:1-12. Epub 2017, Sep 8. B. El Osta, F. Hu, R. Sadek, R. Chintalapally, R., S-C. Tang</p>
Poster Presentations	<p>1. Acute Chest Syndrome in Sickle Cell Disease: Retrospective review of a single center experience. Chintalapally, R., Hongyan, Xu., Patel, N., Kutlar, A. 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting, April 2015. Journal of Sickle Cell Disease and Hemoglobinopathies</p> <p>2. Identification of Nocardia Veterana in patient with no known Immuno compromised State. Chintalapally, R., Parikh, S., Frances, P., Smith, J., Brice, J American College of Physicians Georgia Chapter Conference, October 2014.</p> <p>3. A meta-analysis of immune – related adverse events (irAE) of Immune Checkpoint Inhibitors (ICI) from Cancer Clinical Trials. El-Osta, Badi., Fengjiao Hu., Chintalapally, Rohini., Shou-ching, Tang. European Society of Medical Oncology (ESMO) 2016.</p>
Abstracts (accepted for online publication at ASCO):	<p>1. Clostridium difficile infection in adult patients with Acute Myeloid Leukemia: incidence, recurrence and outcomes. Chintalapally, R., Kukkadapu, T., Parikh S., Mangaonkar, A., Daram, S.</p> <p>2. Acute Acalculous Cholecystitis in Patients with Acute Myeloid Leukemia: Favorable Outcomes with Nonoperative Management. Kukkadapu, T., Chintalapally, R., Parikh s., Mangaonkar, A., Daram, S.</p> <p>3. Prognostic significance of day+14 plasma cell count after initial induction therapy in Acute Myeloid Leukemia. Mangaonkar, A., Chintalapally, R., Mondal, A., Kolhe, R.</p>

Research  
Pharmaceutical  
Trials

Sub Investigator 2017-0758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN 5/2019-Present (Amgen)

Sub Investigator CA209901-Checkmate 901: A phase 3, open-label, randomized study of Nivolumab combined with Ipilumimab, or standard of care chemotherapy, versus standard of care chemotherapy in participants with previously untreated unresectable or metastatic urothelial cancer 5/2019-Present (BMS)

---